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Abstract: Immunotherapeutic and targeted drugs improved survival of patients with metastatic
melanoma. There is, however, a lack of evidence regarding their healthcare costs in clinical practice.
The aim of our study was to provide insight into real-world healthcare costs of patients with metastatic
cutaneous melanoma. Data were obtained from the Dutch Melanoma Treatment Registry for patients
who were registered between July 2012 and December 2018. Mean total/monthly costs per patient
were reported for all patients, patients who did not receive systemic therapy, and patients who
received systemic therapy. Furthermore, mean episode/monthly costs per line of therapy and drug
were reported for patients who received systemic therapy. Mean total/monthly costs were € 89,240/€
6809: € 7988/€ 2483 for patients who did not receive systemic therapy (n = 784) and € 105,078/€ 7652
for patients who received systemic therapy (n = 4022). Mean episode/monthly costs were the highest
for nivolumab plus ipilimumab (€ 79,675/€ 16,976), ipilimumab monotherapy (€ 79,110/€ 17,252), and
dabrafenib plus trametinib (€ 77,053/€ 12,015). Dacarbazine yielded the lowest mean episode/monthly
costs (€ 6564/€ 2027). Our study showed that immunotherapeutic and targeted drugs had a large
impact on real-world healthcare costs. As new drugs continue entering the treatment landscape for
(metastatic) melanoma, it remains crucial to monitor whether the benefits of these drugs outweigh
their costs.
Keywords: metastatic melanoma; healthcare costs; real-world data; immunotherapy; targeted therapy
1. Introduction
The global incidence of cutaneous melanoma has been increasing over the past decades [1]. In The
Netherlands, the estimated incidence rate increased from 8.2 to 24.2 per 100,000 person-years between
1990 and 2018. Most patients (approximately 85%) are diagnosed with localized melanoma and have a
relatively good prognosis. Melanoma has, however, a strong tendency to metastasize, resulting in a
poor prognosis. Historically, one- and five-year survival rates of patients with metastatic melanoma
were only 39% and 12%, respectively [2].
Until 2011, treatment options for metastatic melanoma were limited to chemotherapy
(including dacarbazine and temozolomide) and interleukin-2. However, these drugs never
demonstrated to improve survival [3–5]. Advances in the development of immunotherapeutic
and targeted drugs dramatically changed the treatment landscape. In 2011, the first two new drugs
were approved by the U.S. Food and Drug Administration: ipilimumab (an anti-CTLA-4 antibody) and
vemurafenib (a BRAF inhibitor) [6]. European approval by the European Medicines Agency followed
in the same year for ipilimumab and in 2012 for vemurafenib [7]. Since then, several other drugs and
combinations of drugs have been approved for the treatment of metastatic melanoma (Table S1) [6,7].
Although the new drugs demonstrated to improve survival [8], there is a lack of evidence
regarding their healthcare costs in real-world clinical practice. Previous studies only reported
real-world healthcare costs of ipilimumab and vemurafenib [9–11]. Therefore, the aim of our study
was to provide insight into real-world healthcare costs of patients with metastatic cutaneous melanoma
in The Netherlands since the approval of the new immunotherapeutic and targeted drugs.
2. Results
2.1. Baseline Patient and Tumor Characteristics
A total of 4806 patients were included in our study. The median age was 64 years; 59% of the
patients were male (Table 1). Most patients had a good Eastern Cooperative Oncology Group (ECOG)
performance status (i.e., 0 or 1; 74%), a normal lactate dehydrogenase (LDH) level (58%), and were
diagnosed with M1c disease (69%). More than one-third of the patients with M1c disease had brain
metastases (39%).
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Table 1. Baseline patient and tumor characteristics.
All Patients Patients Who Did NotReceive Systemic Therapy
Patients Who Received
Systemic Therapy
n = 4806 n = 784 n = 4022
Age, years
Mean (SD) 63 (13) 70 (13) 62 (13)
Median (IQR) 64 (54–73) 72 (62–80) 63 (53–71)
Gender, n (%)
Male 2813 (59%) 447 (57%) 2366 (59%)
Female 1992 (41%) 336 (43%) 1656 (41%)
Unknown 1 (0%) 1 (0%) 0 (0%)
ECOG performance status, n (%)
0 2168 (45%) 155 (20%) 2013 (50%)
1 1407 (29%) 193 (25%) 1214 (30%)
≥2 623 (13%) 209 (27%) 414 (10%)
Unknown 608 (13%) 227 (29%) 381 (9%)
LDH level, n (%)
≤1ULN 2773 (58%) 361 (46%) 2412 (60%)
>1 ULN–≤2 ULN 1034 (22%) 136 (17%) 898 (22%)
>2 ULN 619 (13%) 117 (15%) 502 (12%)
Unknown 380 (8%) 170 (22%) 210 (5%)
M category, n (%)
M0 347 (7%) 53 (7%) 294 (7%)
M1a 303 (6%) 28 (4%) 275 (7%)
M1b 466 (10%) 60 (8%) 406 (10%)
M1c 3338 (69%) 488 (62%) 2850 (71%)
Unknown 352 (7%) 155 (20%) 197 (5%)
Brain metastases, n (%)
No 3357 (70%) 460 (59%) 2897 (72%)
Yes 1307 (27%) 285 (36%) 1022 (25%)
Unknown 142 (3%) 39 (5%) 103 (3%)
ECOG = Eastern Cooperative Oncology Group; IQR = interquartile range; LDH = lactate dehydrogenase; n = number;
SD = standard deviation; ULN = upper limit of normal.
Of all patients, 16% (n = 784) did not receive systemic therapy during the study period and 84%
(n = 4022) received at least one systemic therapy. Patients who received systemic therapy had more
favorable baseline patient and tumor characteristics than patients who did not receive systemic therapy.
They were younger (median age: 63 versus 72 years), had more often a good ECOG performance status
(80% versus 44%) and a normal LDH level (60% versus 46%), and had less often brain metastases
(36% versus 58% of the patients with M1c disease).
2.2. Healthcare Costs of All Patients
Table 2 presents the healthcare resource use and costs of all patients (n = 4806). The mean (median)
observation period was 18.0 (12.1) months; 66% of the patients died during this period. Mean total
costs were € 89,240 (standard deviation (SD): € 86,489). Systemic therapy was by far the most important
cost driver, accounting for 83% of the costs (€ 73,998). On average, patients received 1.4 lines of
therapy. The remaining 17% of the costs was related to hospital admissions (6%; € 5363), hospital visits
(5%; € 4287), medical imaging (2%; € 2086), radiotherapy (1%; € 1318), surgery (1%; € 1224), genetic
testing (1%; € 891), hyperthermia (<1%; € 70), and radiofrequency ablation (RFA; <1%; € 2). Mean
monthly costs were € 6809 (SD: € 5783).
2.3. Healthcare Costs of Patients Who Did not Receive Systemic Therapy
The mean (median) observation period of patients who did not receive systemic therapy (n = 784)
was 11.7 (3.7) months (Table 2). Mean total costs were € 7988 (SD: € 7490). These costs were mainly
driven by the costs of hospital admissions, which accounted for 35% of the costs (€ 2831). Almost half
of all admissions (44%) was related to palliative care. The remaining 65% of the costs was attributable
to surgery (15%; € 1160), medical imaging (14%; € 1080), radiotherapy (13%; € 1068), hospital visits
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(13%; € 1010), genetic testing (9%; € 753), hyperthermia (1%; € 83), and RFA (<1%; € 2). Mean monthly
costs were € 2483 (SD: € 3191).
Table 2. Healthcare resource use and costs of all patients.
All Patients Patients Who Did Not ReceiveSystemic Therapy
Patients Who Received Systemic
Therapy
n = 4806 n = 784 n = 4022
Observation period, months
Mean (SD) 18.0 (16.9) 11.7 (17.0) 19.3 (16.6)
Median (IQR) 12.1 (5.4–25.4) 3.7 (1.4–13.2) 13.5 (6.8–26.9)
Deceased patients, % 66% 81% 63%
Mean
resource use
(SD)
Mean costs (SD)
Mean
resource use
(SD)
Mean costs (SD)
Mean
resource use
(SD)
Mean costs (SD)
Medical imaging
CT scan 4.4 (4.1) € 684 (€ 638) 1.7 (2.1) € 264 (€ 331) 5.0 (4.2) € 766 (€ 651)
MRI scan 2.1 (2.4) € 589 (€ 677) 0.9 (1.6) € 270 (€ 458) 2.3 (2.4) € 651 (€ 695)
PET/CT scan 0.8 (1.3) € 813 (€ 1444) 0.5 (1.0) € 546 (€ 1088) 0.8 (1.4) € 865 (€ 1498)
Genetic testing
Gene mutation testing 1.0 (0.2) € 891 (€ 185) 0.8 (0.4) € 753 (€ 365) 1.0 (0.1) € 918 (€ 102)
Hospital visits
Outpatient visit 19.0 (15.6) € 1798 (€ 1480) 7.0 (6.6) € 665 (€ 624) 21.3 (15.8) € 2019 (€ 1497)
Daycare treatment 8.7 (10.5) € 2489 (€ 3020) 1.2 (2.0) € 345 (€ 588) 10.1 (10.9) € 2907 (€ 3124)
Hospital admissions
Inpatient hospital day 10.4 (14.0) € 5150 (€ 6943) 5.4 (8.6) € 2656 (€ 4264) 11.4 (14.6) € 5636 (€ 7253)
Intensive care unit day 0.2 (1.2) € 213 (€ 1531) 0.1 (0.9) € 175 (€ 1098) 0.2 (1.3) € 221 (€ 1602)
Treatment
Surgery 0.4 (0.9) € 1224 (€ 2703) 0.4 (0.8) € 1160 (€ 2654) 0.4 (0.9) € 1236 (€ 2713)
Radiotherapy 0.5 (0.6) € 1318 (€ 1914) 0.4 (0.5) € 1068 (€ 1590) 0.5 (0.7) € 1367 (€ 1968)
Hyperthermia <0.1 (0.1) € 70 (€ 871) <0.1 (0.1) € 83 (€ 949) <0.1 (0.1) € 68 (€ 855)
RFA <0.1 (<0.1) € 2 (€ 61) <0.1 (<0.1) € 2 (€ 53) <0.1 (<0.1) € 3 (€ 62)
Systemic therapy 1.4 (1.2) € 73,998 (€ 80,716) NA NA 1.7 (1.1) € 88,422 (€ 80,682)
Total costs
Mean (SD) € 89,240 (€ 86,489) € 7988 (€ 7490) € 105,078 (€ 85,963)
Median (IQR) € 67,882(€ 22,004–€ 126,953)
€ 5310
(€ 2800–€ 11,131)
€ 83,092
(€ 43,715–€ 141,326)
Monthly costs
Mean (SD) € 6809 (€ 5783) € 2483 (€ 3191) € 7652 (€ 5798)
Median (IQR) € 5692(€ 2584–€ 9443) € 1304 (€ 393–€ 3243)
€ 6526
(€ 3484–€ 10,348)
CT = computed tomography; IQR = interquartile range; MRI = magnetic resonance imaging; n = number; NA = not
applicable; PET = positron emission tomography; RFA = radiofrequency ablation; SD = standard deviation.
Of the patients who did not receive systemic therapy, 81% (n = 634) died during the observation
period and 19% (n= 150) was still alive at the cutoff date. Their baseline patient and tumor characteristics
are presented in Table S2. Deceased patients had less favorable baseline characteristics than patients
who were still alive. They were older (median age: 73 versus 65 years), had less often a good ECOG
performance status (41% versus 58%) and a normal LDH level (43% versus 60%), and were more often
diagnosed with M1c disease (71% versus 27%). Table 3 presents the healthcare costs of these patients.
Mean total costs were lower for deceased patients than for patients who were still alive (€ 7219 versus €
11,237). Their mean monthly costs were, however, much higher (€ 2981 versus € 378). Costs of deceased
patients were mainly driven by the costs of hospital admissions (41%; € 2961). Surgery (27%; € 3039)
and medical imaging (21%; € 2350) were the main cost drivers for patients who were still alive.
2.4. Healthcare Costs of Patients Who Received Systemic Therapy
The mean (median) observation period of patients who received systemic therapy (n = 4022)
was 19.3 (13.5) months; approximately two-thirds of the patients (63%) died during this period
(Table 2). Mean total costs were € 105,078 (SD: € 85,963). Systemic therapy was the main cost driver
(84%; € 88,422), followed by hospital admissions (6%; € 5857), hospital visits (5%; € 4926), medical
imaging (2%; € 2282), radiotherapy (1%; € 1367), surgery (1%; € 1236), genetic testing (1%; € 918),
hyperthermia (<1%: € 68), and RFA (<1%; € 3). Mean monthly costs were € 7652 (SD: € 5798).
Table 4 presents the episode and monthly costs stratified by line of therapy. In total, 2107 patients
received one line of therapy, 1077 patients received two lines of therapy, and 838 patients received
three (or more) lines of therapy. Pembrolizumab was the most frequently prescribed drug in the first
line (21%), ipilimumab in the second line (23%), and dabrafenib plus trametinib in the third line (28%).
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Mean episode costs were the highest for the second line (€ 59,701) and the lowest for the third line
(€ 49,725). The mean monthly costs were also the highest for the second line (€ 11,939), but the lowest
for the first line (€ 8231).
Table 3. Healthcare costs of patients who did not receive systemic therapy stratified by vital status.
Deceased Patients Patients Alive
n = 634 n = 150
Observation period, months
Mean (SD) 5.4 (7.9) 38.2 (19.6)
Median (IQR) 2.6 (1.1–6.3) 37.4 (19.6–58.8)
Mean (SD) Mean (SD)
Medical imaging € 780 (€ 772) € 2350 (€ 2467)
Genetic testing € 778 (€ 343) € 644 (€ 430)
Hospital visits € 797 (€ 881) € 1911 (€ 1076)
Hospital admissions € 2961 (€ 4671) € 2279 (€ 3827)
Treatment
Surgery € 716 (€ 2131) € 3039 (€ 3652)
Radiotherapy € 1083 (€ 1541) € 1003 (€ 1789)
Hyperthermia € 103 (€ 1054) € 0 (€ 0)
RFA € 0 (€ 0) € 10 (€ 122)
Total costs
Mean (SD) € 7219 (€ 6979) € 11,237 (€ 8647)
Median (IQR) € 4720 (€ 2474–€ 9497) € 9262 (€ 4425–€ 15,699)
Monthly costs
Mean (SD) € 2981 (€ 3357) € 378 (€ 345)
Median (IQR) € 1769 (€ 765–€ 4130) € 293 (€ 139–€ 514)
IQR = interquartile range; n = number; RFA = radiofrequency ablation; SD = standard deviation.
Figure 1 presents the episode and monthly costs stratified by drug. Mean episode costs were the
highest for nivolumab plus ipilimumab (€ 79,675; SD: € 44,196), followed by ipilimumab monotherapy
(€ 79,110; SD: € 29,113) and dabrafenib plus trametinib (€ 77,053; SD: € 63,451). Dacarbazine yielded
the lowest mean episode costs (€ 6564; SD: € 5090). The mean monthly costs were also the highest for
nivolumab plus ipilimumab and ipilimumab monotherapy (€ 16,976 and € 17,252, respectively) and
the lowest for dacarbazine (€ 2027). Mean monthly costs were similar between drugs within the same
class: vemurafenib and dabrafenib (€ 6710 and € 6460, respectively), dabrafenib plus trametinib and
vemurafenib plus cobimetinib (€ 12,015 and € 11,947, respectively), and nivolumab and pembrolizumab
(€ 5732 and € 5798, respectively). Detailed results regarding the episode costs stratified by drug are
presented in Table S3.
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Table 4. Episode and monthly costs stratified by line of therapy.
First Line of Therapy Second Line of Therapy Third Line of Therapy
n = 4022 n = 1915 n = 838
Episode duration,
months
Mean (SD) 11.3 (12.3) 8.9 (11.1) 7.6 (9.3)
Median (IQR) 6.6 (3.5–13.7) 4.9 (2.5–9.8) 4.2 (2.5–9.3)
Drug, n (%)
Dacarbazine 154 (4%) 33 (2%) 29 (3%)
Ipilimumab 488 (12%) 440 (23%) 86 (10%)
Nivolumab 412 (10%) 205 (11%) 64 (8%)
Pembrolizumab 830 (21%) 370 (19%) 158 (19%)
Nivolumab plus
ipilimumab 368 (9%) 249 (13%) 46 (5%)
Vemurafenib 540 (13%) 64 (3%) 53 (6%)
Dabrafenib 191 (5%) 85 (4%) 40 (5%)
Dabrafenib plus
trametinib 588 (15%) 286 (15%) 233 (28%)
Vemurafenib plus
cobimetinib 105 (3%) 66 (3%) 50 (6%)
Other 346 (9%) 117 (6%) 79 (9%)
Patients with a
complete episode 1, % 80% 81% 80%
Mean (SD) Mean (SD) Mean (SD)
Medical imaging € 1349 (€ 1145) € 941 (€ 1109) € 806 (€ 937)
Genetic testing € 829 (€ 288) € 10 (€ 94) € 0 (€ 0)
Hospital visits € 2789 (€ 2764) € 2554 (€ 2859) € 2179 (€ 2314)
Hospital admissions € 2993 (€ 5525) € 3206 (€ 5209) € 2805 (€ 4456)
Treatment
Surgery € 527 (€ 1677) € 375 (€ 1552) € 316 (€ 1466)
Radiotherapy € 651 (€ 1269) € 600 (€ 1245) € 574 (€1207)
Hyperthermia € 27 (€ 542) € 23 (€ 497) € 13 (€ 376)
RFA <€ 1 (€ 24) € 1 (€ 34) € 4 (€ 73)
Systemic therapy € 49,336 (€ 49,118) € 51,993 (€ 47,431) € 43,028 (€ 43,465)
Episode costs
Mean (SD) € 58,502 (€ 51,066) € 59,701 (€ 49,380) € 49,725 (€ 45,146)
Median (IQR) € 48,357(€ 22,376–€ 80,885)
€ 50,392
(€ 22,907–€ 85,434)
€ 37,771
(€ 15,370–€ 69,036)
Monthly costs
Mean (SD) € 8231 (€ 7374) € 11,939 (€ 11,463) € 10,366 (€ 10,415)
Median (IQR) € 6587 (€ 3416–€ 11,019) € 8439 (€ 4774–€ 14,877) € 7716 (€ 3974–€ 13,059)
IQR = interquartile range; n = number; RFA = radiofrequency ablation; SD = standard deviation.1 These patients
either died during the line of therapy or received a new systemic therapy.
3. Discussion
This study provides insight into real-world healthcare costs of patients with metastatic cutaneous
melanoma in The Netherlands since the approval of the new immunotherapeutic and targeted drugs.
Mean total costs were € 89,240 (SD: € 86,489). Costs substantially differed between patients who did
not receive systemic therapy (€ 7988) and patients who received systemic therapy (€ 105,078). This
difference was largely owing to the costs of systemic therapy, which accounted for more than 80% of
the costs.
Patients who did not receive systemic therapy were stratified by vital status because we assumed
that these patients either had an infaust prognosis or a rather good prognosis (e.g., patients with
oligometastatic disease). The results of our study confirm this assumption. First, deceased patients had
less favorable baseline patient and tumor characteristics than patients who were still alive (Table S2).
Second, the observation period was much shorter for deceased patients than for patients who were
still alive (mean: 5.4 versus 38.2 months). Finally, hospital admissions were the main cost driver for
deceased patients (41%), whereas costs of patients who were still alive were mainly driven by the costs
of surgery (27%) and medical imaging (21%).
For patients who received systemic therapy, costs were stratified by drug. Although episode
costs differed between drugs within the same class (vemurafenib and dabrafenib, dabrafenib plus
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trametinib and vemurafenib plus cobimetinib, and nivolumab and pembrolizumab), their monthly
costs were similar. This underlines the importance of accounting for differences in episode durations
(and observation periods). Moreover, a network meta-analysis (NMA) showed that effectiveness and
safety were also comparable between drugs within the same class [12]. Therefore, it could be suggested
that clinicians should not be restricted by differences in effectiveness, safety, and costs while choosing
between these drugs.
Furthermore, our study showed that episode costs were similar between ipilimumab monotherapy
and nivolumab plus ipilimumab. This was mainly owing to the costs of ipilimumab, which were higher
for ipilimumab monotherapy (€ 70,976) than for ipilimumab in combination with nivolumab (€ 55,228).
On average, patients received 3.2 cycles of ipilimumab monotherapy compared to 2.6 cycles of
ipilimumab combination therapy. Due to a reasonably comparable episode duration (mean: 9.1 versus
9.6 months), monthly costs were also similar between ipilimumab monotherapy and nivolumab plus
ipilimumab. The previously mentioned NMA showed, however, that effectiveness was in favor of
nivolumab plus ipilimumab, whereas safety was in favor of ipilimumab monotherapy [12]. This
underlines that evidence on effects, costs, and cost-effectiveness is crucial. It will provide insight
into what extends the benefits of drugs outweighing their costs, which may facilitate evidence-based
decision-making in clinical practice.
Three previous studies reported real-world healthcare costs of ipilimumab and vemurafenib. One
of these studies was our own study in which we calculated healthcare costs of all Dutch patients
who received ipilimumab [11]. The two other studies calculated healthcare costs of United States
(US) patients who received ipilimumab or vemurafenib. According to the study by Chang et al. [9],
mean episode costs were US$ 153,062 (≈€ 113,480) for ipilimumab and US$ 77,687 (≈€ 57,597) for
vemurafenib. In the study by Toy et al. [10], mean monthly costs were US$ 35,472 (≈€ 26,718) for
ipilimumab and US$ 17,793 (≈€ 13,402) for vemurafenib. Both of these studies reported considerably
higher costs than our study. It is, however, difficult to compare costs between countries as, for example,
drug use and unit prices may differ. This information was not reported in both studies.
It should be noted that our study has some limitations. First, we used list prices for drugs, and
reference prices and tariffs for other resources. Although these prices may not reflect actual costs
(e.g., nivolumab and pembrolizumab are subjected to a confidential financial arrangement), the use
of these sources is recommended in the Dutch costing manual [13]. Second, we did not include
healthcare costs outside the hospital setting, such as costs of hospice care, which may have led to an
underestimation of the actual healthcare costs. We believe, however, that the impact will be rather
limited because costs were mainly driven by the costs of systemic therapy. Third, approximately 10% of
the patients received at least one investigational drug. Costs of these drugs are paid by pharmaceutical
companies. However, in our study, costs of investigational drugs were only set at zero if the drug was
given in a blinded trial or if the drug was not approved for metastatic melanoma in The Netherlands at
the time of this study. If costs of all investigational drugs were set at zero, mean total costs of patients
who received systemic therapy would have been € 102,450 instead of € 105,078. Finally, costs were
not yet complete for all patients because 34% of the patients were still alive at the cutoff date. These
patients will accrue additional costs during the remainder of their life.
4. Materials and Methods
4.1. Data Source and Patient Population
Data were obtained from the population-based Dutch Melanoma Treatment Registry (DMTR).
The DMTR contains detailed data regarding baseline patient and tumor characteristics, treatment
patterns, healthcare resource use, and survival of all Dutch patients with unresectable stage IIIC or
stage IV melanoma (i.e., metastatic melanoma). In compliance with Dutch regulations, the DMTR was
approved by the medical ethical committee and was not subject to the Medical Research Involving
Human Subjects Act. A detailed description of the DMTR has been previously published [14].
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For this study, we selected all patients (≥18 years) with metastatic cutaneous melanoma who
were registered in the DMTR between July 2012 and December 2018. Patients with incomplete data
regarding the start or stop date of a systemic therapy and/or patients with insufficient follow-up
(i.e., patients who were alive at the cutoff date with an observation period of less than six months)
were excluded. The cutoff date was December 2019.
4.2. Cost Analysis
The cost analysis was conducted from a hospital perspective using the methodology as described
in the Dutch costing manual [13]. Costs were calculated by applying unit costs to individual patient
resource use for the following cost components: medical imaging, genetic testing, hospital visits,
hospital admissions, surgery, radiotherapy, hyperthermia, RFA, and systemic therapy. Missing data
on resource use were imputed using conditional mean imputation. Table 5 presents the unit costs.
Unit costs of medical imaging, genetic testing, surgery, radiotherapy, hyperthermia, and RFA were
based on tariffs issued by the Dutch Healthcare Authority [15]. The unit costs of hospital visits and
hospital admissions were derived from the Dutch costing manual [13]. Drug costs were acquired
from the Z-index (i.e., the Dutch drug database) for two chemotherapeutic drugs (dacarbazine and
temozolomide), three immunotherapeutic drugs (ipilimumab, nivolumab, and pembrolizumab), and
six targeted drugs (vemurafenib, dabrafenib, trametinib, cobimetinib, encorafenib, and binimetinib) [16].
Costs of investigational drugs were set at zero if the drug was given in a blinded trial or if the drug
was not approved for metastatic melanoma in The Netherlands at the time of this study. All costs were
based on Euro 2018 cost data. Where necessary, costs were adjusted to 2018 prices using the consumer
price index from Statistics Netherlands [17].
Table 5. Unit costs.
Resource Unit Cost
Medical imaging
CT scan € 154.21
MRI scan € 285.91
PET/CT scan € 1069.76
Genetic testing
Gene mutation testing 1 € 929.25
Hospital visits
Outpatient visit € 94.69
Daycare treatment € 287.19
Hospital admissions
Inpatient hospital day € 495.30
Intensive care unit day € 1234.08
Surgery
Excision € 95.65
Lymph node dissection € 1734.62
Metastasectomy 2 € 2999.07–€ 6239.07
Radiotherapy
Short course (≤6 sessions) € 2034.13
Standard course (>6 sessions) € 4840.38
Hyperthermia
Hyperthermia € 10,877.17
RFA
RFA € 1490.84
Systemic therapy
Dacarbazine
Vial 500 mg € 46.33
Vial 1000 mg € 87.15
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Table 5. Cont.
Resource Unit Cost
Temozolomide
Capsule 5 mg € 2.60
Capsule 20 mg € 4.80
Capsule 100 mg € 17.40
Capsule 140 mg € 24.00
Capsule 180 mg € 30.40
Capsule 250 mg € 40.20
Ipilimumab
Vial 50 mg € 4250.00
Vial 200 mg € 17,000.00
Nivolumab
Vial 40 mg € 405.03
Vial 100 mg € 1012.56
Vial 240 mg € 2430.15
Pembrolizumab
Vial 50 mg € 1312.18
Vial 100 mg € 2624.37
Vemurafenib
Tablet 240 mg € 30.70
Dabrafenib
Capsule 50 mg € 35.53
Capsule 75 mg € 52.16
Trametinib
Tablet 0.5 mg € 54.19
Tablet 2 mg € 203.81
Cobimetinib
Tablet 20 mg € 86.89
Encorafenib
Capsule 50 mg € 24.41
Capsule 75 mg € 36.05
Binimetinib
Tablet 15 mg € 34.09
Investigational drug 3 € 0.00
CT = computed tomography; mg = milligram; MRI = magnetic resonance imaging; PET = positron emission
tomography; RFA = radiofrequency ablation. 1 BRAF, NRAS, KIT, GNAQ, and GNA11. 2 Ranging from € 2999.07
for soft tissue metastases to € 6239.07 for pancreatic metastases. 3 Costs of investigational drugs were set at zero if
the drug was given in a blinded trial or if the drug was not approved for metastatic melanoma in The Netherlands
at the time of this study.
4.3. Data Analysis
Baseline patient and tumor characteristics were summarized using descriptive statistics. Age was
presented as mean and SD as well as median and interquartile range. Gender, ECOG performance
status, LDH level, M category (i.e., site of distant metastases according to the seventh edition of the
American Joint Committee on Cancer staging manual), and brain metastases were presented as counts
and proportions.
Costs were reported for all patients irrespective of their treatment status. To provide further
details, costs were also separately reported for patients who did not receive systemic therapy during
the study period stratified by vital status (dead or alive) and patients who received at least one systemic
therapy stratified by line of therapy and drug. Due to low numbers of patients, costs were only
separately reported for the first, second, and third lines. Similarly, costs were not separately reported
for temozolomide and encorafenib plus binimetinib. Mean (SD) total costs per patient were calculated
from the diagnosis of metastatic melanoma until death or last follow-up (i.e., the observation period).
Mean (SD) episode costs per line of therapy and drug were calculated from the diagnosis of metastatic
melanoma or the start of a systemic therapy until the start of a new systemic therapy, death, or last
follow-up (i.e., the episode duration). To account for differences in observation periods or episode
durations, costs were also reported as mean (SD) monthly costs. These costs were calculated by
dividing the total costs by the observation period and the episode costs by the episode duration. All
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analyses were conducted using STATA statistical analysis software, version 16.0 (StataCorp. 2019.
Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC, Texas, USA).
5. Conclusions
Our study showed that immunotherapeutic and targeted drugs had a large impact on real-world
healthcare costs of patients with metastatic melanoma. Compared to dacarbazine, episode costs were
five times higher for dabrafenib and 12 times higher for nivolumab plus ipilimumab, ipilimumab
monotherapy, and dabrafenib plus trametinib. As new drugs continue entering the treatment landscape
for (metastatic) melanoma, it remains crucial to monitor whether the benefits of these drugs outweigh
their costs.
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